Searched for
SAROGLITAZAR MG
Torrent, Zydus in co-marketing pact for liver disease drug SaroglitazarTorrent Pharmaceuticals and Zydus Lifesciences formed a licensing and supply pact to co-market Saroglitazar Mg, the sole approved treatment...- Zydus, Lupin enter licensing pact to market drug to treat liver diseaseZydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them. Lupin will pay Zydus upfront licensing...
- Lupin, Zydus Lifesciences ink licensing, supply pact for Saroglitazar MgLupin and Zydus Lifesciences entered into a licensing and supply agreement to co-market Saroglitazar Mg, an innovative drug approved by Ind...
- Zydus starts trial to generate data on effect of Saroglitazar Mg in NAFLD patientsZydus Lifesciences has launched a real-world data registry trial to determine the benefits of its liver drug, Saroglitazar Magnesium, on pa...
- Cadila Healthcare Q2 results: Net profit zooms over 6-fold to Rs 3,002 cr on one-time gainConsolidated total revenue from operations of the company stood at Rs 3,784.8 crore for the quarter under consideration. It was Rs 3,658.9 ...
- Cadila Healthcare Q1 results: Net profit rises 29% to Rs 587 crConsolidated total revenue from operations stood at Rs 4,025.4 crore for the quarter under consideration against Rs 3,514.6 crore for the s...
- European Medicines Agency grants Orphan Drug Designation to Zydus Cadila's Saroglitazar MgOrphan Drug status in Europe is given to medicines with the potential to be safe and effective treatments for rare, life-threatening, or ch...
- USFDA grants orphan drug designation to Zydus Cadila's Saroglitazar MgZydus Cadila, which is a part of Cadila Group, said orphan drug designation provides eligibility for certain development incentives, includ...
- Zydus Cadila receives DCGI nod for NAFLD drug Saroglitazar Mg in IndiaNon-Alcoholic Fatty Liver Disease (NAFLD) is a progressive disease of the liver, which starts with fat accumulation in the liver in patient...
- Zydus Cadila gets USFDA Fast Track Designation for SaroglitazarDrug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug c...
- Zydus Cadila files NDA for Saroglitazar MagnesiumNASH is a progressive disease of the liver and a significant unmet medical need. There are currently no treatments available for the treatm...
- Zydus gets USFDA nod for phase II trials of liver drugThis development underlines the group's commitment to bridging unmet healthcare needs with innovative therapies.
- Zydus gets USFDA nod for clinical trials of Sarolitazar"USFDA has endorsed company's plan to initiate a phase II clinical trial of Saroglitazar in patients with severe hypertriglyceridemia," Zyd...
Load More
